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Abstract
Background: Human endogenous retroviruses (HERVs) comprise approximately 8% of the human genome and
while the majority are transcriptionally silent, the most recently integrated HERV, HERV-K (HML-2), remains active.
During HIV infection, HERV-K (HML-2) specific mRNA transcripts and viral proteins can be detected. In this study, we
aimed to understand the antibody response against HERV-K (HML-2) Gag in the context of HIV-1 infection.
Results: We developed an ELISA assay using either recombinant protein or 164 redundant “15mer” HERV-K (HML-2)
Gag peptides to test sera for antibody reactivity. We identified a total of eight potential HERV-K (HML-2) Gag immuno‑
genic domains: two on the matrix (peptides 16 and 31), one on p15 (peptide 85), three on the capsid (peptides 81, 97
and 117), one on the nucleocapsid (peptide 137) and one on the QP1 protein (peptide 157). Four epitopes (peptides
16, 31, 85 and 137) were highly immunogenic. No significant differences in antibody responses were found between
HIV infected participants (n = 40) and uninfected donors (n = 40) for 6 out of the 8 epitopes tested. The antibody
response against nucleocapsid (peptide 137) was significantly lower (p < 0.001), and the response to QP1 (peptide
157) significantly higher (p < 0.05) in HIV-infected adults compared to uninfected individuals. Among those with HIV
infection, the level of response against p15 protein (peptide 85) was significantly lower in untreated individuals con‑
trolling HIV (“elite” controllers) compared to untreated non-controllers (p < 0.05) and uninfected donors (p < 0.05). In
contrast, the response against the capsid protein (epitopes 81 and 117) was significantly higher in controllers com‑
pared to uninfected donors (p < 0.001 and <0.05 respectively) and non-controllers (p < 0.01 and <0.05). Peripheral
blood mononuclear cells (PBMCs) from study participants were tested for responses against HERV-K (HML-2) capsid
recombinant peptide in gamma interferon (IFN-γ) enzyme immunospot (Elispot) assays. We found that the HERV-K
(HML-2) Gag antibody and T cell response by Elispot were significantly correlated.
Conclusions: HIV elite controllers had a strong cellular and antibody response against HERV-K (HML-2) Gag directed
mainly against the Capsid region. Collectively, these data suggest that anti-HERV-K (HML-2) antibodies targeting cap‑
sid could have an immunoprotective effect in HIV infection.
Keywords: HIV, HERV-K, Antibodies, Gag, Elite Controllers, Viremic non-controllers
Background
Human endogenous retroviruses (HERVs) are fossil remnants of inherited retroviruses which were endogenized
into the genome, and comprise about 5–8% of the
human genome [1]. Their ability to replicate or produce
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infectious particles is impaired by host restriction [2,
3] and they are now considered to be stably integrated,
largely silent, and transmitted in a Mendelian fashion [4].
Three major HERV classes have been identified and classified according to their polymerase gene (pol) sequence
homology with exogenous retroviruses. Class I, II and
III HERVs have similarities with gammaretroviruses,
betaretroviruses and spumaviruses, respectively [5]. To
date, endogenous homologues to lentiviruses have not
been described in the human genome.
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provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license,
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

de Mulder et al. Retrovirology (2017) 14:41

Page 2 of 9

viremic non-controllers (VNCs) and HIV-negative low
risk donors (SNLR). This response correlated with the
HERV-K (HML-2) capsid T cell response. We mapped
the antibody response and characterized an antibody
pattern signature in ECs that significantly differed from
the ones found VNCs, suggesting that the anti-HERV-K
(HML-2) antibody response could play a role in the control of infection.

HERV-K (HML-2), a class II HERV, with gag, pro, pol
and env genes, flanked by two Long Terminal Repeats
(LTR), is the most recently integrated into the genome
and under certain circumstances can express proteins
[6, 7]. HERV-K (HML-2) expression has been associated
with some autoimmune diseases [8–13] and cancers [14–
19], and mRNA transcripts and proteins can be found in
tumor tissues. Translated HERV proteins can induce an
immune response that correlates with disease progression or regression in some cancers [20–25].
We, and others, have previously shown that HERV-K
(HML-2) can be reactivated in HIV infection [26–28].
The mechanisms leading to HERV-K (HML-2) expression are still being elucidated, but HIV Vif and Tat proteins have been implicated [27, 29]. However, it appears
that the transactivation of HERV-K by exogenous HIV is
more complex than initial studies suggested. In a previous study, we showed that HIV induced a skewed expression of HERV-K (HML-2) Env which favored the surface
cell expression of the transmembrane envelope glycoprotein (TM) at the expense of the surface unit (SU). We
showed that isolated HERV-K specific T-cell clones and
HA137, a human anti-HERV-K (HML-2) TM antibody,
eliminated HIV infected cells in vitro [26–28, 30, 31].
To further characterize the role of the anti-HERV-K
(HML-2) immune response in HIV infection, we investigated the antibody response to HERV-K (HML-2) Gag in
HIV infected participants. In this study, we showed that
strong anti-HERV-K (HML-2) capsid response is more
frequently found in elite controllers (ECs) compared to
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We first evaluated the antibody response against HERVK (HML-2) recombinant capsid protein in uninfected
donors and in untreated HIV-infected participants who
were categorized as ECs or VNCs (Fig. 1). Although no
significant differences were found in the magnitude of
the antibody response between HIV-infected adults and
HIV-negative low risk donors (SNLR), when the HIVinfected cohort was classified according to clinical status,
we found that ECs had significantly higher level of antibodies against HERV-K (HML-2) capsid compared to
SNLR (p < 0.01, Kruskal–Wallis test) and VNC (p < 0.001,
Kruskal–Wallis test) (Fig. 1a). Since 85% of ECs developed a moderate or a strong anti-HERV Gag B-cell
response (compared to 15% for VNCs), we investigated
whether ECs also had a T-cell response against HERV-K
(HML-2) Gag. We found that the HERV-K (HML-2) Gag
antibody and T-cell response by Elispot were significantly
correlated (p = 0.0047, Spearman test) (Fig. 1b).

b

***

1.5

SNLR

The anti‑HERV‑K (HML‑2) Capsid response correlates
with anti‑HERV Gag T‑cell response in elite controllers

Anti-HERV-K recombinant
capsid IgGs (OD)

Anti-HERV-K recombinant
capsid IgGs (OD)

a

Results

VNC

2

r=0.6791
p=0.0047

1.5

**

1

0.5
0
0

1000

2000

3000

4000

SFU/million PBMCs (SMP)
Fig. 1 Comparison of antibody response against HERV-K (HML-2) recombinant capsid protein (a). Detection of antibodies against recombinant
HERV-K (HML-2) capsid protein was performed by ELISA assay for 40 seronegative low risk healthy donors (SNLR) and 80 chronic HIV subjects: 40
elite controllers (EC) and 40 viremic non-controllers (VNC). Individual dots represent the mean of 4 independent experiments. Correlation of capsid
specific T cell responses in elite controllers (b). Both specific T cell and antibody responses were assayed by Elispot and ELISA respectively using the
recombinant HERV-K (HML-2) protein for 18 elite controllers. Individual dots represent the mean of 4 independent experiments for the ELISA assay.
The statistical significance between the different groups was established using a Kruskal–Wallis and Dunn’s Multiple Comparison test for A and a
non-parametric Spearman test for B. A p value <0.05 was considered as significant. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
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Identification of linear antibody epitopes on HERV‑K
(HML‑2) Gag proteins

Elite controllers and viremic non‑controllers have distinct
antibody patterns

To further characterize anti-HERV-K (HML-2) Gag
responses during HIV infection we used a set of 164
redundant “15mer” peptides overlapping by 11 amino
acids in a peptide-based ELISA assay to map immunogenic domains. We used sera from 8 SNLR and confirmed
that HIV uninfected donors had a low basal level of antibodies against HERV-K (HML-2) Gag, as previously published [32]. Among all tested peptides, 8 sequences had
significant differences with the basal level. We identified
4 sequences with a higher reactivity with human sera and
4 sequences associated with a lower reactivity (Table 1;
Fig. 2; Additional file 1: Fig. S1). The epitopes are distributed on HERV-K (HML-2) Gag as follows: two epitopes
on matrix (MA, peptides 16 and 31), one epitope on p15
(peptide 85), three epitopes on capsid (CA, peptides 81,
97 and 117), one epitope on nucleocapsid (NC, peptide
137) and one epitope on the QP1 protein (peptide 157).
These results suggest that each protein domain has different antibody immunogenicity to HERV-K (HML-2)
proteins (Fig. 2). Indeed, sera from SNLR participants
strongly reacted to the nucleocapsid epitope but not to
the capsid (Fig. 2). Thus, domains can be classified as
poorly immunogenic, such as the capsid or the QP1 and
QP2 proteins, or immunogenic such as matrix, p15 and
nucleocapsid.

We then used the eight peptide epitopes identified above
to perform a serological screen on 40 HIV-infected and
40 SNLR sera samples (Fig. 3). The differences between
these two groups were not significant for 6 out of 8
epitopes (Fig. 3). The responses against MA (peptides
16 and 31) and p15 (peptide 58) were either slightly
decreased or not changed upon HIV infection (Fig. 3a–
c). However, the response against the most immunogenic
domain (peptide 137) was significantly lower (p < 0.001,
q = 0.0004, Kruskal–Wallis test) in HIV infected subjects
Table 1 Sequence identification of HERV-K (HML-2) Gag
epitopes
Epitope

Sequence

Protein

Immunogenicity

16

KRIGKELKQAGRKGN

MA

Medium

31

KKSQKETESLHCEYV

MA

Medium

58

GYPGMPPAPQGRAPY

P15

Medium

81

GVKQYGPNSPYMRTL

CA

Low

97

NPPVNIDADQLLGIG

CA

Low

117

SIADEKARKVIVELM

CA

Low

137

KCYNCGQIGHLKKNC

NC

High

157

PIQPFVPQGFQGQQP

QP1

Low

MA matrix, CA capsid, NC nucleocapsid

IgGs (490nm OD)

1.5

****

1

0.5

****

****

****
***
*

*

**

CA

NC

QP2

p15

QP1

MA

SP1

1
4
7
10
13
16
19
21
22
25
28
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9
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Fig. 2 Antibody mapping of anti-HERV-K (HML-2) responses in healthy donors. Sera from 8 seronegative low risk healthy donors (SNLR) were used
for antibody epitope identification by ELISA. The 7 sub-units: matrix (MA), SP1, p15, capsid (CA), nucleocapsid (NC) and QP 1 and 2 are represented
by 164 redundant 15mers named by their number corresponding to their rank in the list. The lines represent the average of the 8 individuals and
duplicate signals (OD). Background was determined by the average of OD from each peptide. The statistical significance between the different
groups was established using a Kruskal–Wallis and Dunn’s Multiple Comparison test and a p value <0.05 was considered as significant. *p < 0.05;
**p < 0.01; ***p < 0.001; ****p < 0.0001
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Fig. 3 Anti-HERV-K (HML-2) antibodies in HIV infection. The detection of total IgG against HERV-K (HML-2) gag was performed for 40 seronega‑
tive low risk healthy donors (SNLR white dots) and 80 chronically HIV infected subjects (HIV black dots) by peptide-based ELISA using sequences
determined in Fig. 2 and represented by their number on the top of each graph (a–h). Each graph represents ELISA for one linear epitope. Error
bars represent SEM. The statistical significance between the different groups was established using the Mann–Whitney u test. The figure shows the
representative results of at least three independent experiments. A p value <0.05 was considered as significant. *p < 0.05; **p < 0.01; ***p < 0.001. In
parenthesis is indicated the adjusted p value (q) regarding the 3 independent experiments using original method of Benjamini and Hochberg with
a Q of 5%. The number of independent observations is represented by n

(Fig. 3g). Although the response against peptide 97 did
not differ based on HIV status, the response against the
two other epitopes present on the capsid, peptide 81 and
117, trended towards being higher in those infected with
HIV (p = 0.05, q = 0.07 and p = 0.08, q = 0.1 respectively, Kruskal–Wallis test) (Fig. 3d–f ). The response
against peptide 157 from the QP1 protein was the only
that was significantly higher among those with HIV infection (p < 0.05, q = 0.01 Kruskal–Wallis test) (Fig. 3h).
To better understand the potential role of these antibody responses in HIV infection, we categorized the
cohort based on clinical status. We used sera samples
from 20 elite controllers (ECs) and 20 viremic noncontrollers (VNCs). No differences were observed for
the responses against peptides 16, 31, 97, 137 and 157
(Fig. 4a, b, e, g, h). However, significant differences were
observed for the response against p15 (peptide 58).
The response was significantly lower in elite controllers compared to SNLR (p < 0.05, Kruskal–Wallis test)
and VNCs (p < 0.05, Kruskal–Wallis test), while there
was no difference between VNCs and SNLR (Fig. 4c). In

contrast, antibody responses against capsid epitopes 81
and 117 were significantly higher in ECs compared to
SNLR (p < 0.001 and <0.05, respectively, Kruskal–Wallis test) and VNCs (p < 0.01 and <0.05, Kruskal–Wallis
test), but no differences were detected between VNCs
and SNLR (Fig. 4f ). We found that 90% of ECs had a
moderate or a strong response against peptide 81 (25%
for VNCs). Furthermore, we found a positive correlation for responses against capsid epitopes 81 and 117
(p = 0.0122, r = 0.5768, Spearman test) in ECs that was
not found in VNCs (Fig. 5a). However, compared to the
response against peptide 58, we found a trend towards
an inverse relationship between the antibody responses
against HERV-K (HML-2) capsid and p15 developed in
VNCs. Collectively, the data show that VNCs and ECs
developed different anti-HERV-K (HML-2) gag antibody
responses (Fig. 5b, c).
When analyzing the different groups according to their
clinical status we found that VNC had low levels of anticapsid antibodies, and there was a significant inverse
correlation between the anti peptide 81 or anti-HERV-K

de Mulder et al. Retrovirology (2017) 14:41

a

16

1.5

n=6

ns

Page 5 of 9

b

31

0.4

n=6

ns

0.2

IgGs (490nm OD)

1.0
0.0

0.1

SNLR

e

EC

VNC

ns

0.5

0.0

SNLR

EC

f

97

0.4

ns

*

0.3

0.3

VNC

117

0.4

n=3

n=4

*

SNLR

EC

*

*

d

81

0.5

n=4

0.3

0.3

0.2

0.2

0.1

0.1

0.0

SNLR

EC

g

137

2.5

***
n=7

**

ns

***

0.4

VNC

0.0

SNLR

VNC

157
ns

0.3

ns

**

EC

h

*

n=3

ns

0.2

1.0

0.1

0.5

0.0

0.0

n=7

1.5

0.1

0.1

0.5

ns

2.0

0.2

0.2

58

0.4

0.3

0.5

c

0.0

0.0

VNC

SNLR

EC

VNC

SNLR

EC

VNC

SNLR

EC

VNC

Fig. 4 Anti-HERV-K (HML-2) capsid response in HIV infection. The detection of total IgG against HERV-K (HML-2) gag was performed for 40 seron‑
egative low risk healthy donors (SNLR white dots), 40 elite controllers (EC grey dots) and 40 viremic non-controllers (VNC thin black dots) by peptidebased ELISA using sequences determined in Fig. 2. Each graph represents ELISA for one linear epitope and represented by their number on the top
of each graph (a–h). Error bars represent SEM. The figure shows the representative results of at least three independent experiments. The statistical
significance between the different groups was established using a Kruskal–Wallis and Dunn’s Multiple Comparison test and a p value <0.05 was
considered as significant. *p < 0.05; **p < 0.01; ***p < 0.001
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Fig. 5 Anti-HERV-K (HML-2) response correlations. The correlation between the anti-capsid and anti-p15 responses was determined by comparing
the responses against the peptides 81 and 117 for the capsid and 58 for p15 measured by peptide-based ELISA for 20 elite controllers (a) and 20
viremic non controllers (b, c). The statistical significance between the different responses was established using the non-parametric Spearman test.
The figure shows the representative results of four independent experiments. A p value <0.05 was considered as significant. *p < 0.05

(HML-2) recombinant capsid responses and HIV viremia
(p = −0.4879, r = 0.0291 and p = 0.0056, r = −0.5955
respectively, Spearman test) (Fig. 6). However, no correlation between CD4+T cell counts and anti-HERV-K
(HML-2) Gag responses were detected, either in ECs or
in VNCs (data not shown).

Discussion
We, and others, have previously shown that HIV infection reactivates HERV-K (HML-2), leading to HERV-K
(HML-2) Gag and Env protein production [27, 33]. In
this study, we hypothesized that HIV infection leads to a
HERV-K (HML-2) capsid antibody response. We focused
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Fig. 6 Correlations between HIV viremia and anti-HERV-K (HML-2) capsid responses. The correlation between the anti-HERV-K (HML-2) capsid
response and viral load was determined by comparing the responses against peptide 81 (a) and the recombinant HERV-K (HML-2) capsid protein
(b) measured by peptide-based ELISA for 20 viremic non-controllers. The statistical significance between the different responses was established
using the non-parametric Spearman test. Figure 6a shows a representative result of four independent experiments. Figure 6b shows the mean of
four independent experiments. A p value <0.05 was considered as significant. *p < 0.05; **p < 0.01

on responses to HERV-K (HML-2) capsid based on our
previous findings that elite controllers (EC) developed an
anti-HERV-K (HML-2) capsid cellular immune response
[30]. We show here that a strong antibody response
against HERV-K (HML-2) capsid can be detected in
ECs. To better characterize the anti-HERV-K (HML-2)
response, we mapped responses to linear epitopes on the
full HERV-K (HML-2) Gag sequence. Responses against
HERV-K (HML-2) Gag were not changed by HIV infection, except for responses to an epitope present on the
QP1 protein (epitope 157), which were higher in HIV-1
infected participants compared to controls. The antibody
response against nucleocapsid (epitope 137) was significantly lower in HIV infected participants compared to
uninfected individuals.
When we compared the anti-HERV-K (HML-2) gag
antibody response between ECs and VNCs, we saw a distinct antibody pattern, characterized by a significantly
higher anti-capsid antibodies (specific to peptides 81
and 117) and lower anti-p15 antibodies (epitope 58) in
controllers. The plasma HIV RNA levels were strongly
inversely correlated in VNCs who had an anti-HERV-K
(HML-2) capsid response.
It has been previously established that HERV-K (HML2) expression is tightly associated with HIV viral transcription and activity in vitro and in vivo [31, 34–37].
However, ECs have limited HIV replication activity, suggesting that the induction of the anti HERV-K (HML-2)
capsid response in ECs is not caused by HIV-induced
HERV-K capsid expression, as has been previously
described for the HERV-K (HML-2) envelope antibody
response [31, 36, 37]. However, a longitudinal study would
be more informative to determine potential causality.

In a previous report, we showed that expression of
HERV-K Env proteins following HIV infection is skewed
towards a predominant expression of the HERV-K transmembrane protein compared to the surface unit protein
[31]. This suggested an HIV/HERV-K (HML-2) interaction far more complex than previous studies have proposed. In the case of HERV-K (HML-2) Gag expression,
antibody profiles found in VNCs and ECs seem to reinforce this complexity. Anti-HERV-K (HML-2) capsid
responses in VNCs are not significantly different than
those found in controls, but they seem to be lower in
early and late stages of HIV infection despite an increase
of HERV-K (HML-2) expression. Patients who naturally
control HIV infection are more likely to have a strong
antibody response against HERV-K capsid, but the antibody response against p15 (peptide 58) was strongly
decreased in ECs compared to VNCs and SNLR. Further
longitudinal studies are needed to understand the chronology and the cause of this dichotomy.
A second objective of our study was to characterize the role of anti HERV-K (HML-2) capsid responses
in ECs. Antibodies against viral gag proteins are not
unexpected in HIV patients [38] and the anti-HIV p24
response correlates with control of disease progression
[38]. Antibodies against capsid could bind cells resulting
in their lysis and formation of immunocomplexes. Those
immunocomplexes might interact with innate immune
cells such as NK cells, macrophages or dendritic cells
and promote their activation and induction of a cellular
immune response [39, 40]. This may explain why both T
and B cell responses directed against HIV p24 correlated
with the status of controllers. A similar hypothesis could
be applied for anti-HERV-K (HML-2) capsid antibodies,
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with EC having both an anti-HIV p24 and an anti-HERVK (HML-2) capsid response as a way to reinforce their
antiviral response.

Conclusion
In this study, we identified linear immunogenic antibody
epitopes on HERV-K (HML-2) gag proteins. We found
that elite controllers had a distinctive antibody pattern
compared to viremic non-controllers and HIV seronegative participants. Although further studies are needed to
elucidate how these responses could be involved in the
control of viremia, it reinforces the importance of studying HERV-K (HML-2) capsid immune responses in HIV
infection.
Methods
Study populations

Samples of peripheral blood mononuclear cells (PBMCs)
were selected from participants in a San Francisco-based
HIV-infected cohort: OPTIONS (n = 40). Samples from
HIV-negative controls were obtained from individuals
who donated blood to the Stanford blood bank. Studies
were performed on cryopreserved PBMCs and sera.
PBMC and sera samples were obtained from the following categories of chronically HIV-infected individuals: 20 elite controllers (EC: naive for treatment,
undetectable viral load for two years, CD4 > 350) and
20 untreated virologic non-controllers (VNC; naive for
treatment, viral load >2000 copies/mL).
ELISA

A set of 164 overlapping “15-mer” HERV-K (HML-2) Gag
peptides (JPT Peptide Technologies, Berlin, Germany),
based on HERV-K102 sequence (AF164610), were used
to comprehensively map the HERV-K (HML-2) antibody
response (Additional file 2: Fig. S2). Positive signals were
confirmed by peptides produced by two other companies (New England Peptide and Gene Script). 96 microtiter wells plate (Nunc-Immuno Plate MaxiSorp Surface)
were coated for 1 h at 37 °C with peptides at 10 μg/ml
in PBS or over-night at 4 °C with recombinant protein
(GeneArt) at 5 μg/ml in PBS. Plates were then washed 3
times with 200 μL of PBS/0.05%-Tween 20 and blocked
with 100 μL of blocking buffer (PBS/2.5%-BSA) at room
temperature (RT). The samples were diluted in blocking
buffer and incubated 2 h at RT in duplicates. Plates were
then washed 3 times with 200 μL of PBS/0.05%-Tween
20. An anti-human IgG or anti-human IgM HRP-conjugated secondary antibody was diluted at 1:1000 in blocking buffer and incubated at RT for 1 h. Plates were then
washed 6 times with 200 μL of PBS/0.05%-Tween 20 and
incubated for 10 min with 100 μL of TMB (Invitrogen).
Addition of 50 μL H2SO4 2 M stopped the reaction. The
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plates were read at 450 and 690 nm for the background
on a plate reader. Background from 690 nm uncoated
wells and twice the background from 450 nm PBSBSA (negative control) were subtracted from the mean
absorbance of the coated wells (corrected OD). For the
detection of anti-Gag antibodies, sera were used at 1:400.
ODs were normalized with serum from a high responder
in a standard curve. The STDEV intra experiment was
less than 4%.
For the response against the recombinant HERVK (HML-2) capsid and the peptide 81, we defined the
humoral responses for elite controllers as followed: the
response was considered moderate if the corrected OD
is greater than the mean of corrected OD for SNLR and
strong if the corrected OD is greater than twice the mean
of corrected OD for SNLR.
ELISPOT assays

The ELISPOT assay has been described previously [30].
In brief, 96-well plates (Millipore, Billerica, MA) were
coated with human monoclonal anti-interferon gamma
(IFN-γ) immunoglobulin (Mabtech, Mariemont, OH).
After plates were washed and blocked with 10% fetal
calf serum, PBMCs were added at a concentration of 1
 05
cells per well. Duplicate wells were prepared for each
experimental condition. Spot totals for duplicate wells
were averaged, and all spot numbers were normalized to
numbers of (IFN-γ) spot forming units (SFU) per million
PBMCs (SPM). The spot values from medium control
wells were subtracted, after which a positive response to
a peptide was defined as 50 SPM and 2 times the medium
control value. The total magnitude of the HERV T cell
response was calculated by adding up all of the individual
peptide SPM values.
Statistical analyses

To assess the distribution of the humoral responses
obtained in this study, we used the D’Agostino and Pearson normality test. The results concluded that the populations were not normally distributed. According to this
statement, we used non-parametric statistical tests to
compare the humoral responses assayed by ELISA for
each group. Multiple comparisons were performed in the
3 groups (SNLR, EC and VNC) with the Kruskal–Wallis
and Dunn’s multiple comparison test for Fig. 4. Spearman correlation analyses were used to measure associations between different humoral responses and HIV viral
load or CD4+T cells count for Figs. 1b, 5, and 6. The
two-tailed Mann–Whitney u test was used to compare
the humoral responses between HIV-1pos and HIV-1neg
(SNLR) groups for Fig. 3. A q value was calculated using
the original method of Benjamini and Hochberg and
added on the figure when it was relevant. All tests were
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conducted using GraphPad Prism, version 6.00 (GraphPad Software, San Diego, CA), with the statistical significance of the findings set at a p value of less than 0.05.

Additional files
Additional file 1: Fig. S1. Antibody mapping of anti-HERV-K (HML-2)
responses in study participants groups. Sera from Healthy donors, Elite
Controllers and Viremic non-controllers were used for antibody epitope
identification by ELISA. The 7 sub-units: matrix (MA), SP1, p15, capsid (CA),
nucleocapsid (NC) and QP 1 and 2 are represented by 164 redundant
15mers named by their number corresponding to their rank in the list. The
lines represent the average of the 8 individuals and duplicate signals (OD).
Background was determined by the average of OD from each peptide.
Peptides giving a signal significantly decreased are symbolized in grey and
peptides giving a signal significantly increased are symbolized in black.
Additional file 2: Fig. S2. Strategy for designing overlapping peptides.
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